Namodenoson: A New Hope in Anti-Obesity Treatment
Namodenoson is an oral drug with a proven favorable safety profile
Can-Fite BioPharma Ltd., a pioneering biotechnology company, has exciting news regarding its lead drug candidate, Namodenoson. This innovative oral drug, which is being developed to treat Metabolic Dysfunction-associated Steatohepatitis (MASH) and various cancers, recently received significant recognition in the form of a patent allowance from the Australian Patent Office.
Patent Approval Details
The patent application entitled "An A3 adenosine receptor ligand for use for achieving a fat loss effect" has been accepted and is set to expire in 2040. This patent solidifies the protection of Namodenoson for its use in treating obesity, paving the way for broader applications of this transformative drug.
Implications of the Patent
This intellectual property covers methods for treating obese patients through oral administration of Namodenoson. The application is based on compelling data showing how Namodenoson interacts with fat cells, demonstrating a reduction in fat levels thanks to the increase of the hormone adiponectin, which plays a crucial role in fat regulation within the body.
In animal studies, Namodenoson reduced body weight significantly when subjects were fed a high-fat diet. A clinical study of Phase IIa for MASH patients further illustrated this potential by showcasing a 2.3% weight loss following a three-month course of treatment, alongside a notable rise in serum adiponectin levels.
Company Insights and Future Prospects
Dr. Pnina Fishman, CSO and Chairperson of Can-Fite, expressed enthusiasm over the patent approval, indicating it will bolster the company’s product protection strategies. Namodenoson is currently under evaluation in Phase IIb studies, focusing on its efficacy in obese patients with MASH. This could reveal critical insights into its anti-obesity effects as the clinical study progresses.
The Growing Market for Obesity Treatments
The global market for obesity treatment is thriving, highlighted by a recent valuation of USD 12 billion in 2023. Australia alone is projected to have approximately 1.85 million patients struggling with MASH, underlining the need for effective treatments like Namodenoson.
Understanding Namodenoson
Namodenoson is characterized as a small, orally bioavailable drug that specifically targets the A3 adenosine receptor (A3AR), which is found in higher concentrations in diseased cells compared to healthy ones. This unique action resonates with the favorable safety profile observed in clinical studies.
Clinical Applications of Namodenoson
The drug is not only pivotal in addressing obesity but also shows promise in pivotal Phase III trials for advanced liver cancer, and there are plans for Phase IIa studies targeting pancreatic cancer. Its design aims to tap into multi-billion-dollar markets related to cancer and inflammatory diseases, indicating a robust future for Can-Fite BioPharma.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. is dedicated to advancing clinical-stage drug development, making strides in the treatment of cancer and liver diseases with a focus on innovative solutions. Apart from Namodenoson, their pipeline includes Piclidenoson, which recently showed positive results in a Phase III trial for psoriasis. The company's commitment to safety and efficacy is underscored by the extensive clinical experience with over 1,600 patients studied to date.
Contact Information
For inquiries or further information, please reach out to:
Can-Fite BioPharma
Motti Farbstein
Email: info@canfite.com
Phone: +972-3-9241114
Frequently Asked Questions
What is Namodenoson used for?
Namodenoson is used for treating obesity, MASH, and certain types of cancers.
What has the recent patent approval achieved?
The patent allows enhanced protection for Namodenoson’s use in obesity treatment, valid until 2040.
How has Namodenoson performed in clinical studies?
Namodenoson has shown positive results, including weight loss and increased adiponectin levels in clinical trials.
What is the market outlook for obesity treatments?
The global obesity treatment market is valued at USD 12 billion, reflecting growing awareness and demand.
How do I contact Can-Fite BioPharma?
You can contact Can-Fite BioPharma via email at info@canfite.com or by phone at +972-3-9241114.
